Category for posts not assigned a category.
The company flagged additional revenue opportunities in the year ahead as it establishes traction as the leading B2B supplier in the Australian cannabis market as the supply agreement with Canngea finalised. Leading medicinal cannabis company ECS Botanics (ASX:ECS) continues to execute on a rapid growth trajectory, as it gains traction as the supplier of choice for a…
Dear shareholders, FY21 has been a defining year for the company as we start to leverage assets that we have established in proceeding years. These include our production base, industry leading team and culture, intellectual property and systems. As a result, the company is at a major inflection point. We are now in a position…
Noosa is set to become the home of one of four new medicinal cannabis clinics and three dispensaries providing support for patients from the Brisbane region through to the Sunshine Coast. Releaf Clinics are set to open in Caloundra, Noosa, Mooloolaba and Fortitude Valley over the next four months with Caloundra slated to open first…
Managing Director, Alex Keach breaks down the demand dynamics for medicinal cannabis & GMP complaint products, as ECS Botanics Holdings looks to execute on a global market opportunity. After a multi-year period of development, the pieces are now in place for Australia to become a global leader in the production, sale and export of medicinal cannabis, ECS Botanics’ Managing…
Australia has the potential to become the international gold standard for production of medicinal marijuana and multiple ASX-listed companies are seeking to benefit. – Is medical marijuana legal in Australia: Manufacturing of medicinal cannabis products has been legal in Australia since 2016-Australian revenue from medicinal cannabis projected to double in 2021 to $200m-Australia has the potential…
The Northern Territory is exploring whether its warm winter weather could deliver an edge in Australia’s emerging industrial hemp market. Industrial hemp is an environmentally sustainable crop that can be used in thousands of products including building materials, textiles and beer. NT growers could be well-positioned to produce dry season fibre crops to supply southern…
In every sector of culture and society, a shift towards greater diversity is moving the needle on what, and who is considered “typical”. This is as true in the realm of cannabis consumption as anywhere else, with the stereotype of surfer dude stoners and glazed and confused couch potatoes making way for women as the…
ECS Botanics Holdings has secured a 5-year $4.5 million deal to supply Polish company Alivio Spolka with the GMP manufactured Medicinal Cannabis. Shares in ECS Botanics Holdings (ASX:ECS) have jumped almost 5% today after the company announced it secured a five-year agreement with Polish company Alivio Spolka for the supply of $4.5 million worth of GMP manufactured…
Colombia is set to permit the export of medical cannabis flower for the first time in what could be a significant development for the global industry. Cultivating in an ideal equatorial climate which allows for quintuple annual harvests, with low labour costs, will see flower prices significantly undercutting global competition. In the United States the…
Investing in ASX listed cannabis companies is not for the faint-hearted. As 2020 has shown, it is always accompanied by volatility. With the industry still in its infancy, setbacks are inevitable – and this past year was no exception for many companies on the Top 20 asx listed cannabis companies list. In many ways it…
ECS Botanics asx ecs has filled senior roles across Australia, Oceania and Europe. As it pursues a global distribution strategy, cannabis producer ECS Botanics asx ecs has put a focus through the middle part of this year on bolstering the strength of its management team. And this morning the company provided an important update on the hiring…
Medical cannabis accessibility grows as Tasmania becomes the last Australian state to legalise over the counter medical cannabis.
Hype around the de-scheduling of low dose medicinal cannabis from a Schedule 4 to an over-the-counter Schedule 3 drug but added that steps needed to be taken before such a drug hits the market
Terpenes play an important role in the aroma and flavour of a cannabis strain, and they work in synergy with cannabinoids and other cannabis plant compounds to produce psychoactive effects.
Researchers in the US have started what is the country’s first double-blind, randomized, placebo-controlled study examining the effect of cannabis products on severe migraine symptoms.
A new University of Adelaide trial will explore the use of personalised medicinal cannabis dosing to prevent common and impactful symptoms of treatment in advanced cancer thanks to Federal Government funding of $1.5 million
Frequent cannabis users engaged in more physical activity than non-current users.
The Therapeutic Goods Administration (TGA) has issued a new warning to consumers about the risks of buying black market medicinal cannabis products online, stating they may be unsafe, of poor quality or contain a different dose than that claimed on the label. The advice on the TGA website says: “Beware of buying medicines online. It may seem…
From May 1, Australians living with a rare form of epilepsy will have access to a medicinal cannabis medicine.
ECS Botanics plans major expansion of Tasmanian cannabis farm ECS Botanics (ASX: ECS) has submitted plans to the Office of Drug Control to expand its Tasmanian cannabis farm by more than 100 times its current area. If approved, ECS’ cannabis cultivation area would be expanded from 2,500sqm to 320,000sqm an Australian first according to managing…
